Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Gastrointestinal problems experienced by type 1 diabetes patients could be treated with an experimental drug that inhibits insulin-like growth factor binding protein 3.
Patients with type 1 diabetes commonly experience gastrointestinal symptoms, which can be severe. However, the underlying mechanism of disease, known as diabetic enteropathy, is unknown.
New research, published in Cell Stem Cell (2015;17:486–498)[1], found that patients with type 1 diabetes and diabetic enteropathy have high levels of insulin-like growth factor binding protein 3 (IGFBP3), which is antiproliferative and promotes stem cell death in the intestinal lining, damaging its structure.
http://www.pharmaceutical-journal.c...ry-raises-hopes-of-treatment/20069501.article
Patients with type 1 diabetes commonly experience gastrointestinal symptoms, which can be severe. However, the underlying mechanism of disease, known as diabetic enteropathy, is unknown.
New research, published in Cell Stem Cell (2015;17:486–498)[1], found that patients with type 1 diabetes and diabetic enteropathy have high levels of insulin-like growth factor binding protein 3 (IGFBP3), which is antiproliferative and promotes stem cell death in the intestinal lining, damaging its structure.
http://www.pharmaceutical-journal.c...ry-raises-hopes-of-treatment/20069501.article